NIH Funding Opportunities
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 1 hour 13 min ago
Notice of Correction to RFA-DA-20-002 "Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Linked Research Project Sites (Collaborative U01 Clinical Trial Not Allowed)"
Notice NOT-DA-19-032 from the NIH Guide for Grants and Contracts
Notice NOT-CA-19-043 from the NIH Guide for Grants and Contracts
Notice of Preapplication Webinar for Administrative Supplements for Activities to Promote Human Immune-Representing Oncology Models
Notice NOT-CA-19-040 from the NIH Guide for Grants and Contracts
International Research Ethics Education and Curriculum Development Award (R25 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-244 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The goal of this FIC R25 program is to support educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications, by strengthening research ethics capacity in low- and middle-income countries (LMICs) through increasing the number of LMIC research intensive institutions that can provide advanced education in research ethics.
Funding Opportunity PAR-19-243 from the NIH Guide for Grants and Contracts. The overall goal of this initiative is to support the development of a sustainable critical mass of bioethics scholars in low and middle-income country (LMIC) research intensive institutions with the capabilities to conduct original empirical or conceptual ethics research that addresses challenging issues in health research and research policy in these countries as well as provide research ethics leadership to their institutions, governments and international research organizations. FIC will support LMIC-U.S. collaborative institutional bioethics doctoral and postdoctoral research training programs that incorporate didactic, mentored research and training components to prepare multiple individuals with ethics expertise for positions of scholarship and leadership in health research institutions in the LMIC
Notice of Change in Expiration Date of PAR-19-229 "Informatics Methodology and Secondary Analyses for Immunology Data in ImmPort (UH2 Clinical Trial Not Allowed)"
Notice NOT-AI-19-055 from the NIH Guide for Grants and Contracts
Notice of Change to Response Date for NOT-NS-19-045 " Request for Information: Soliciting Input on How Best to Advance Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Research"
Notice NOT-NS-19-057 from the NIH Guide for Grants and Contracts
Notice of Correction to Eligibility Information in PAR-18-947 "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01)"
Notice NOT-CA-19-042 from the NIH Guide for Grants and Contracts
NICHD Guidance for Investigator-initiated Basic Experimental Studies Involving Humans (BESH) That Meet NIH's Definition of a Clinical Trial
Notice NOT-HD-19-012 from the NIH Guide for Grants and Contracts
Notice NOT-MH-19-027 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-OD-19-020 from the NIH Guide for Grants and Contracts. The NIH Office of Research on Women's Health (ORWH) and participating NIH Institutes and Centers invite institutional career development award applications for Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Career Development Programs, hereafter termed "Programs". Programs will support mentored research career development of junior faculty members, known as BIRCWH Scholars, who have recently completed clinical training or postdoctoral fellowships, and who will be engaged in interdisciplinary basic, translational, behavioral, clinical, and/or health services research relevant to the health of women and, where appropriate, the use of both sexes to better understand the influence of sex as a biological variable on health and disease. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development. The clinical trial must be a NIH-defined clinical trial. Scholars may also propose fundamental research or human subjects research that is not a clinical trial.
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
Funding Opportunity RFA-CA-19-047 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. Projects proposed in response to this FOA must be applicable to one of the following areas: (1) cancer therapeutics; (2) cancer imaging technologies, interventional devices, and/or in vivo diagnostics; or (3) in vitro and ex vivo cancer diagnostics and prognostics. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required
BRAIN Initiative: Tools to Facilitate High-Throughput Microconnectivity Analysis (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-MH-20-135 from the NIH Guide for Grants and Contracts. The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate tools and resources to facilitate the detailed analysis of brain microconnectivity. Novel and augmented techniques are sought that will ultimately be broadly accessible to the neuroscience community for the interrogation of microconnectivity in healthy and diseased brains of model organisms and humans. Development of technologies that will significantly drive down the cost of connectomics would enable routine mapping of the microconnectivity on the same individuals that have been analyzed physiologically, or to compare normal and pathological tissues in substantial numbers of multiple individuals to assess variability. Advancements in both electron microscopy (EM) and super resolution light microscopic approaches are sought. Applications that propose to develop approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged. Proof-of-principle demonstrations and/or reference datasets enabling future development are welcome, as are improved approaches for automated segmentation and analysis strategies of neuronal structures in EM images.no
Oral Health in People Living with HIV and Additional Non-Communicable Diseases (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DE-20-001 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages research to address gaps in our knowledge of the oral health status of people living with HIV (PLWH) with an emphasis on PWLH who also have non-communicable diseases (NCDs). It supports efforts to understand the combined effects of HIV, antiretroviral therapy (ART), and NCDs on oral health, and it encourages identification of approaches for prevention and treatment of oral diseases and assessment of treatment outcomes in PLWH with or without NCDs. These efforts could help to generate evidence for oral health treatment guidelines tailored to the needs of dental patients with HIV.
Funding Opportunity PAR-19-242 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.
Accelerating Medicine Partnership in Parkinsons disease (AMP PD) unbiased proteomics biofluid analysis (U01 Clinical Trials Not Allowed)
Funding Opportunity RFA-NS-19-028 from the NIH Guide for Grants and Contracts. The purpose of the FOA is to support unbiased proteomics analysis of matched longitudinal CSF and plasma samples from the Accelerating Medicine Partnership in Parkinson's disease (AMP PD) cohorts using a data independent acquisition (DIA) mass spectrometry platform, with the ultimate goal of identifying PD biomarkers for diagnosis, prognosis and progression. Proteomics data and workflows generated through this initiative will be broadly shared with the research community through the AMP PD Knowledge Portal to enable additional analyses and data integration across the various datatypes available through AMP PD. The proteomics analysis will be staged to include identification of pre-analytical variables, that will inform the optimal handling of 4,500 CSF and plasma samples.
Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional)
Funding Opportunity PAS-19-241 from the NIH Guide for Grants and Contracts. The Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) program is intended to promote innovative, high quality, interdisciplinary research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK here invites investigator-initiated research project grant applications (R01s) in specific areas of basic, translational and clinical research in specific benign urologic conditions and diseases where needs and opportunities for progress are particularly timely. Specific research topic areas supported by the SUITOR program, as outlined below, will change over time and will be updated annually through the NIH Guide to Grants and Contracts.
Notice NOT-HS-19-013 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-19-039 from the NIH Guide for Grants and Contracts. Neuroinflammation triggered by brain trauma, neurodegenerative diseases and neurotoxicant-induced CNS disorders initiates CNS innate immune responses that activate inflammasomes. Inflammasomes are high molecular weight complexes in the cytosol of stimulated immune cells that mediate the activation of inflammatory cascades. In response to insults, Nod-like receptors (NLRs) recruit adaptor proteins and caspase-1 to assemble inflammasomes and process the release of pro-inflammatory cytokines IL-1?, IL-18 and IL-33. Recent evidence suggests that chronic drug exposure, i.e., cocaine, methamphetamine and morphine, can induce inflammasome activation primarily mediated by NLRP3 within microglia. Additionally, emerging data suggest that HIV-1 infection can also prime inflammasome activation. Drug abuse, especially in association with HIV-1 infection, induces ROS production, impairs blood brain barrier integrity, and promotes monocyte transmigration. These upstream events exert synergistic effects that prime oligomerization and activation of inflammasome and release of pro-inflammatory cytokine IL-1?. The scientific objective of this research is to delineate the role of inflammasomes in neuropathology produced by chronic drug exposure and HIV infection. Understanding the involvement of inflammasome in the immune activation may help identify molecular markers and immune cells associated with HIV-1 disease progression among substance abuse populations, and identify novel targets for intervention to treat neuroinflammation and immune dysregulation aroused in these processes.
Funding Opportunity RFA-HL-20-014 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to fund research centers that will establish longitudinal cohorts in rare HLBS diseases to investigate unaddressed research questions using epidemiologic study designs and methods that are appropriate for conditions affecting fewer than 200,000 persons in the US. These observational cohort studies should be designed to provide an evidence base for future interventional studies, including clinical trials; for developing better diagnostics than those that are currently available; for answering early translational questions; or for broader implementation of guidelines for managing these diseases. This program will provide opportunities to advance rare disease research using genetics and deep phenotyping to characterize the disease and to identify disease sub-types; to use data science methods that integrate clinical and patient-reported outcomes (PROs) with laboratory, imaging, environmental and -omics data to understand the natural history of disease; to generate data that differentiate patients with the same morphological phenotype but different genetic mutations and severity of outcomes; to elucidate genotype-phenotype interactions and multisystem phenotyping to develop reliable and valid predictive tools to determine who will respond to which treatments and when to intervene; and to encourage innovative methods such as telemedicine to include participants with rare diseases located in remote locations. This initiative will allow applicants to study related rare diseases, disorders, conditions or syndromes together based on pathogenesis, affected biochemical, cellular or physiological features or organ system involvement. Studying related rare diseases within the same cohort could help understand the nuances, and knowledge gained from one disease and could accelerate the advances in related diseases. For example, investigators may propose to study hemoglobin disorders rather than only sickle cell anemia or thalassemia.
NIH Funding Opportunities
- Notice of NIAAA's Participation in PAR-19-246 "Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Abuse and Addiction Scientists (R25 - Clinical Trials Not Allowed)
- Notice of Correction to PAR-19-246 "Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Abuse and Addiction Scientists (R25 - Clinical Trials Not Allowed)"
- Notice of Special Interest (NOSI): Understanding Factors in Infancy and Early Childhood (Birth to 24 months) That Influence Obesity Development
- Methods to Improve Reproducibility of Human iPSC Derivation, Growth and Differentiation (SBIR) (R44 Clinical Trial Not Allowed)
- Required Use of the xTRACT System to Prepare Data Tables for Training Grant Research Performance Progress Reports in FY 2020